These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12401764)

  • 1. Cost-effectiveness of two screening programs for microalbuminuria in type 2 diabetes.
    Lepore G; Maglio ML; Nosari I; Dodesini AR; Trevisan R
    Diabetes Care; 2002 Nov; 25(11):2103-4; author reply 2104. PubMed ID: 12401764
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of tests for microalbuminuria screening in patients with diabetes.
    Incerti J; Zelmanovitz T; Camargo JL; Gross JL; de Azevedo MJ
    Nephrol Dial Transplant; 2005 Nov; 20(11):2402-7. PubMed ID: 16105865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economics of screening for microalbuminuria in patients with insulin-dependent diabetes mellitus.
    Borch-Johnsen K
    Pharmacoeconomics; 1994 May; 5(5):357-60. PubMed ID: 10147227
    [No Abstract]   [Full Text] [Related]  

  • 4. Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland.
    Kessler R; Keusch G; Szucs TD; Wittenborn JS; Hoerger TJ; Brügger U; Wieser S
    Swiss Med Wkly; 2012; 142():w13508. PubMed ID: 22307760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening, monitoring, and treatment of albuminuria: Public health perspectives.
    de Jong PE; Curhan GC
    J Am Soc Nephrol; 2006 Aug; 17(8):2120-6. PubMed ID: 16825331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
    Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
    Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of screening for and treating albuminuria in individuals without diabetes or hypertension: are we moving beyond the evidence?
    Mangione F; Esposito C; Dal Canton A
    Am J Kidney Dis; 2010 Oct; 56(4):801; author reply 801-2. PubMed ID: 20851319
    [No Abstract]   [Full Text] [Related]  

  • 8. Microalbuminuria and diabetes.
    Killalea D
    BMJ; 1993 Aug; 307(6902):507. PubMed ID: 8400961
    [No Abstract]   [Full Text] [Related]  

  • 9. Screening for microalbuminuria in patients with type 2 diabetes is incomplete in general practice.
    Knudsen ST; Mosbech TH; Hansen B; Kønig E; Johnsen PC; Kamper AL
    Dan Med J; 2012 Sep; 59(9):A4502. PubMed ID: 22951198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microalbuminuria and mortality in type 2 diabetes.
    Strayer SM
    J Fam Pract; 1998 Aug; 47(2):89-90. PubMed ID: 9722786
    [No Abstract]   [Full Text] [Related]  

  • 11. Screening for microalbuminuria to prevent nephropathy in patients with diabetes: a systematic review of the evidence.
    Scheid DC; McCarthy LH; Lawler FH; Hamm RM; Reilly KE
    J Fam Pract; 2001 Aug; 50(8):661-8. PubMed ID: 11509158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [What decisions to make in view of microalbuminuria in a diabetic?].
    Marre M; Bouhanick B; Berrut G; Fabbri P
    Journ Annu Diabetol Hotel Dieu; 1996; ():193-7. PubMed ID: 8965422
    [No Abstract]   [Full Text] [Related]  

  • 13. Microalbuminuria among patients with type II diabetes mellitus: early screening and intervention required.
    Khuwaja AK
    Hong Kong Med J; 2005 Feb; 11(1):70. PubMed ID: 15687523
    [No Abstract]   [Full Text] [Related]  

  • 14. Microalbuminuria in controlled type 2 diabetes mellitus patients.
    Adedapo KS; Abbiyesuku FM; Adedapo AD; Osotimehin BO
    Afr J Med Med Sci; 2001 Dec; 30(4):323-6. PubMed ID: 14510112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies and cost-effectiveness evaluation of persistent albuminuria screening among high-risk population of chronic kidney disease.
    Wang H; Yang L; Wang F; Zhang L
    BMC Nephrol; 2017 Apr; 18(1):135. PubMed ID: 28420333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of screening for proteinuria.
    Gansevoort RT; de Jong PE; Postma MJ
    JAMA; 2004 Mar; 291(12):1442-3; author reply 1443. PubMed ID: 15039405
    [No Abstract]   [Full Text] [Related]  

  • 17. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease.
    Yarnoff BO; Hoerger TJ; Simpson SK; Leib A; Burrows NR; Shrestha SS; Pavkov ME;
    BMC Nephrol; 2017 Mar; 18(1):85. PubMed ID: 28288579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for microalbuminuria in type 2 diabetes: a reconsideration.
    Soonthornpun S; Leelawattana R; Thamprasit A; Rattarasarn C; Setasuban W; Thammakumpee N
    J Med Assoc Thai; 2002 May; 85(5):604-11. PubMed ID: 12188392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microalbuminuria screening for detecting chronic kidney disease in the general population: a systematic review.
    Wu HY; Huang JW; Peng YS; Hung KY; Wu KD; Lai MS; Chien KL
    Ren Fail; 2013; 35(5):607-14. PubMed ID: 23534678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for microalbuminuria by use of microproteinuria.
    Khatami Z; McIlveen DW; Nesbitt SG; Young IS
    East Mediterr Health J; 2005 May; 11(3):358-65. PubMed ID: 16602454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.